Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | CCR5 | P51681 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6658472 | 0.95 | PDE4B (0.61) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL148503 | 0.89 | PDE4B (0.58) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6655492 | 0.89 | PDE4B (0.53) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL144556 | 0.87 | PDE4B (0.62) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL144193 | 0.87 | PDE4B (0.62) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL142621 | 0.87 | PDE4B (0.62) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6656651 | 0.87 | PDE4B (0.62) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL145391 | 0.87 | PDE4B (0.61) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL144444 | 0.86 | PDE4B (0.54) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL143334 | 0.86 | PDE4B (0.60) | PDE4BPDE4DPDE4APDE4CPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070529-A1 | Use of type 4 phosphodiesterase inhibitors in myocardial diseases | MERK PANTENT GMBH (DE) | 2005-03-31 | — | — | US | claimed |
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2004-12-23 | — | — | US | claimed |
| EP-1368035-A1 | USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES | MERCK PATENT GmbH (DE) | 2003-12-10 | — | — | EP | claimed |
| WO-2002072103-A1 | USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES | MERCK PATENT GMBH (DE) | 2002-09-19 | — | — | WO | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| WO-2005065686-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2005-07-21 | — | — | WO | disclosed |
| US-20050070529-A1 | Use of type 4 phosphodiesterase inhibitors in myocardial diseases | MERK PANTENT GMBH (DE) | 2005-03-31 | — | — | US | disclosed |
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2004-12-23 | — | — | US | disclosed |
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1463509-A1 | TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | MERCK PATENT GmbH (DE) | 2004-10-06 | — | — | EP | disclosed |
| EP-1368035-A1 | USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES | MERCK PATENT GmbH (DE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003037349-A1 | TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2003-05-08 | — | — | WO | disclosed |
| EP-0763534-B1 | Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GMBH (DE) | 2003-02-26 | — | — | EP | disclosed |
| WO-2002072103-A1 | USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES | MERCK PATENT GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
| US-5859008-A | Arylalkyl diazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-01-12 | — | — | US | disclosed |
| EP-0763534-A1 | Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GmbH (DE) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | PDE4B 1040/4885PDE4D 1229/4885PDE4A 1401/4885 |
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | PDE4A, PDE3A, PDE3B | PDE4B 4/4885PDE4D 12/4885PDE4A 1/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | PDE4B 1040/4885PDE4D 1229/4885PDE4A 1401/4885 |
| US-20050070529-A1 | Use of type 4 phosphodiesterase inhibitors in myocardial diseases | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4D 4/4885PDE4A 1/4885 |
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4D 4/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.